4.8 Article

Bioorthogonal nanozymes for breast cancer imaging and therapy

期刊

JOURNAL OF CONTROLLED RELEASE
卷 357, 期 -, 页码 31-39

出版社

ELSEVIER
DOI: 10.1016/j.jconrel.2023.03.032

关键词

Bioorthogonal catalysis; Bioorthogonal nanozymes; Nanocatalysts; Prodrug activation; Pro-fluorophore activation; Anticancer therapy; LA-ICP-MS imaging

向作者/读者索取更多资源

Bioorthogonal catalysis via transition metal catalysts (TMCs) allows the production of therapeutics locally through chemical reactions that are inaccessible to biological systems. This localized approach can improve the effectiveness of anticancer treatment and minimize off-target effects. By encapsulating TMCs into nanomaterials, nanozymes are created to activate imaging and therapeutic agents. In this study, cationic bioorthogonal nanozymes were used to establish localized drug factories for cancer therapy in vivo. These nanozymes remained at the tumor site for at least seven days after a single injection due to interactions with cell membranes and tissue components. The non-toxic prodrugs were then systemically administered and continuously converted into active drugs by the nanozymes. This strategy significantly reduced tumor growth in an aggressive breast cancer model, with reduced liver damage compared to traditional chemotherapy.
Bioorthogonal catalysis via transition metal catalysts (TMCs) enables the generation of therapeutics locally through chemical reactions not accessible by biological systems. This localization can enhance the efficacy of anticancer treatment while minimizing off-target effects. The encapsulation of TMCs into nanomaterials gen-erates nanozymes to activate imaging and therapeutic agents. Here, we report the use of cationic bioorthogonal nanozymes to create localized drug factories for cancer therapy in vivo. These nanozymes remained present at the tumor site at least seven days after a single injection due to the interactions between cationic surface ligands and negatively charged cell membranes and tissue components. The prodrug was then administered systemically, and the nanozymes continuously converted the non-toxic molecules into active drugs locally. This strategy substantially reduced the tumor growth in an aggressive breast cancer model, with significantly reduced liver damage compared to traditional chemotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据